Weak transient response of chronic uveitic macular edema to intravitreal bevacizumab (Avastin)

Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema

“…20,26,27 The safety of intravitreal bevacizumab has been confirmed by previous animal studies and human trials, 28,29 and intravitreal injection of bevacizumab has recently been reported to be effective in macular oedema of various etiologies. 20,[30][31][32][33] Results of our study suggest that intravitreal bevacizumab injection appears to be effective in the primary treatment of DME. In our study, 24 eyes showed an improvement in VA with a decrease in fluorescein leakage on FFA (Figure 1a and b).…”

Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab

“…Thus, at week 4, even though seven eyes still showed an improvement in vision when compared to baseline, only three eyes remained at their best visual acuity achieved after bevacizumab treatment, suggesting that the effect of intravitreal bevacizumab is only transient in most patients treated, as already described. [14][15][16] A reduction of retinal thickness was seen in all eyes in week 1 or 2. The mean retinal thickness, as measured by OCT, was 586.7±97 mm before bevacizumab treatment.…”

“…[14][15][16] All studies used bevacizumab, a humanized monoclonal antibody that targets VEGF. Cordero Coma et al 15 who treated 13 eyes of 13 patients found an improvement of vision in 62% of his patients after a single dose of bevacizumab.…”

Intravitreal Bevacizumab During Pregnancy

“…[1][2][3] The theoretical systemic risks of arterial thromboembolic events in the elderly that may be associated with intravitreal injection of antivascular endothelial growth factor therapy have been described 4-6 but have not deterred treatment because of the significant visual and functional gains that far exceed outcomes with the previous treatment modalities of thermal laser photocoagulation and photodynamic therapy. Intravitreal antivascular endothelial growth factor therapy is gaining acceptance as a beneficial treatment for choroidal neovascularization (CNV) from etiologies other than age-related macular degeneration, [7][8][9][10][11][12][13] cystoid macular edema associated with uveitis, 14,15 retinal vein occlusions, 16,17 and diabetic retinopathy. [18][19][20] These additional indications make the treatment of younger patients much more frequent.…”